FDA clearance propels Filana toward Phase 2a for TSC epilepsy in 2027
FDA's removal of the clinical hold clears Filana's path to a Phase 2a study for simufilam in TSC-related epilepsy, with first patient screening planned for 1Q2027. The milestone follows a December 2025 hold and is supported by Yale IP licensing and a strategic rebrand, positioning Filana for near-term upside if the trial design and early safety data meet expectations, though outcomes remain uncertain.
View signal analysis